|
| Researchers investigated the mechanism by which insulin action and nitric oxide production in endothelial cells could improve systemic bioenergetics and decrease atherosclerosis via differentiation of perivascular progenitor cells into brown adipocytes. [Circulation Research] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Using combined genetic fate tracing with confocal imaging and single-cell RNA sequencing of this niche in homeostasis and during heart failure, investigators unravelled cell type specific transcriptomic changes in fibroblast, endothelial, pericyte and vascular smooth muscle cell subtypes. [Nature Communications] |
|
|
|
| The authors tracked individual P-selectin molecules released at the surface of live endothelial cells following stimulated secretion. [Nature Communications] |
|
|
|
| Scientists defined the regulatory relationship of peripheral nerves on vasculature in a severe extremity trauma model in mice, which resulted in aberrant cell fate and heterotopic ossification. [Bone Research] |
|
|
|
| Investigators presented a microfluidic model of vascularized glioblastoma featuring a tumor spheroid in direct contact with self-assembled vascular networks comprising human endothelial cells, astrocytes, and pericytes. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| The authors utilized induced pluripotent stem cell (iPSC)-derived human brain microvascular endothelial cells to study virus-blood-brain barrier interactions. [Cell Reports] |
|
|
|
| Scientists found that hypoxia increased inhibin levels in ovarian cancer cell lines, xenograft tumors, and patients, and that hypoxia regulated inhibin promoted tumor growth, endothelial cell invasion, and permeability. [Communications Biology] |
|
|
|
| Researchers uncovered the post-attachment biological events elicited in brain microvascular endothelial cells by domain III. [Scientific Reports] |
|
|
|
|
| The authors highlight the materials advances that have enabled transformative progress in vascular engineering by ushering in new tools for both visualizing and building vasculature. [Nature Reviews Materials] |
|
|
|
|
| AffaMed Therapeutics announced that the first patient has been dosed in its US Phase I study of AM712, a novel proprietary bispecific biologic molecule blocking both VEGF and angiopoietin-2 for the treatment of retinal diseases. [AffaMed Therapeutics] |
|
|
|
|
| October 3 – 5, 2022 Vancouver, British Columbia, Canada |
|
|
|
|
|
| H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
| UC Davis – Davis, California, United States |
|
|
|
|
| National Institutes of Health – Bethesda, Maryland, United States |
|
|
|
|